Spero Therapeutics (SPRO) News Today $0.75 +0.01 (+1.03%) As of 01:49 PM Eastern Add Compare Share Share Headlines Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrendsBuy This Stock All Sources Trusted Sources MarketBeat Benzinga Bloomberg GuruFocus MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha TalkMarkets The Street TipRanks The Wall Street Journal Wall Street Zen Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative Most Recent April 2025 March 2025 February 2025 January 2025 December 2024 November 2024 October 2024 September 2024 August 2024 July 2024 June 2024 May 2024 April 2024 March 2024 February 2024 January 2024 December 2023 November 2023 October 2023 September 2023 August 2023 July 2023 June 2023 May 2023 April 2023 March 2023 February 2023 January 2023 December 2022 November 2022 October 2022 September 2022 August 2022 July 2022 June 2022 May 2022 Time Period Spero Therapeutics Analyst RatingsApril 7, 2025 | benzinga.comTD Cowen Sticks to Their Hold Rating for Spero Therapeutics (SPRO)April 2, 2025 | markets.businessinsider.comWe're Keeping An Eye On Spero Therapeutics' (NASDAQ:SPRO) Cash Burn RateMarch 29, 2025 | finance.yahoo.comSpero Therapeutics reports Q4 EPS (38c), consensus (31c)March 28, 2025 | markets.businessinsider.comSpero Therapeutics, Inc.: Spero Therapeutics Announces Fourth Quarter and Full Year 2024 Operating Results and Provides a Business UpdateMarch 28, 2025 | finanznachrichten.deSpero Therapeutics, Inc. (SPRO) Q4 2024 Earnings Call TranscriptMarch 27, 2025 | seekingalpha.comSpero Therapeutics Announces Fourth Quarter and Full Year 2024 Operating Results and Provides a Business UpdateMarch 27, 2025 | globenewswire.com1SPRO : A Glimpse of Spero Therapeutics's Earnings PotentialMarch 26, 2025 | benzinga.comSpero Therapeutics to Report Fourth Quarter and Full Year 2024 Financial Results and Provide Business Update on Thursday, March 27, 2025March 18, 2025 | globenewswire.comUPDATE – Spero Therapeutics to Present at TD Cowen 45th Annual Health Care ConferenceFebruary 25, 2025 | globenewswire.comSpero Therapeutics to Present at TD Cowen 45th Annual Health Care ConferenceFebruary 25, 2025 | globenewswire.comSpero Therapeutics CEO sells shares worth $121,159February 6, 2025 | msn.comSpero Therapeutics, Inc. (NASDAQ:SPRO) CFO Esther Rajavelu Sells 20,689 SharesFebruary 6, 2025 | insidertrades.comSpero therapeutics CFO sells $16,137 in stockFebruary 6, 2025 | msn.comSpero Therapeutics COO Timothy Keutzer sells shares for $44,097February 6, 2025 | msn.comOptimistic Buy Rating for Spero Therapeutics Amid Strategic Initiatives and PartnershipsJanuary 30, 2025 | markets.businessinsider.comSpero Therapeutics Inc SPROJanuary 16, 2025 | morningstar.comSpero Therapeutics, Inc.: Spero Therapeutics Provides Business Update and Announces Interim Leadership ChangesJanuary 10, 2025 | finanznachrichten.deSpero Therapeutics announces interim leadership changesJanuary 10, 2025 | markets.businessinsider.comSpero Therapeutics Makes Interim Changes To Management After Wells Notice From SECJanuary 10, 2025 | markets.businessinsider.comSpero Therapeutics names Esther Rajavelu as Interim President and CEOJanuary 10, 2025 | msn.comSpero Therapeutics Provides Business Update and Announces Interim Leadership ChangesJanuary 10, 2025 | globenewswire.comSpero Therapeutics (NASDAQ:SPRO) Stock Passes Below Two Hundred Day Moving Average - Time to Sell?Spero Therapeutics (NASDAQ:SPRO) Stock Price Crosses Below 200-Day Moving Average - What's Next?December 28, 2024 | marketbeat.comSpero Therapeutics (SPRO) was downgraded to a Hold Rating at Evercore ISIDecember 23, 2024 | markets.businessinsider.comSpero Therapeutics downgraded at Evercore on lack of capital allocation clarityDecember 20, 2024 | markets.businessinsider.comEvercore ISI Group Downgrades Spero Therapeutics (SPRO)December 20, 2024 | msn.comWhat 4 Analyst Ratings Have To Say About Spero TherapeuticsDecember 20, 2024 | benzinga.comEvercore ISI Downgrades Spero Therapeutics (NASDAQ:SPRO) to In-LineEvercore ISI downgraded Spero Therapeutics from an "outperform" rating to an "in-line" rating and set a $5.00 target price on the stock. in a research report on Friday.December 20, 2024 | marketbeat.comSpero Therapeutics (NASDAQ:SPRO) Stock Crosses Below Two Hundred Day Moving Average - Should You Sell?Spero Therapeutics (NASDAQ:SPRO) Share Price Passes Below 200-Day Moving Average - What's Next?December 13, 2024 | marketbeat.comHC Wainwright Issues Pessimistic Estimate for SPRO EarningsSpero Therapeutics, Inc. (NASDAQ:SPRO - Free Report) - Research analysts at HC Wainwright lowered their FY2024 earnings estimates for Spero Therapeutics in a report released on Monday, December 2nd. HC Wainwright analyst R. Selvaraju now forecasts that the company will post earnings per share ofDecember 4, 2024 | marketbeat.comBuy Rating Reiterated for Spero Therapeutics Amid Promising Trial Progress and Strategic PartnershipDecember 3, 2024 | markets.businessinsider.comTD Cowen Downgrades Spero Therapeutics (SPRO)November 19, 2024 | msn.comSpero Therapeutics downgraded to Hold from Buy at TD CowenNovember 18, 2024 | markets.businessinsider.comSpero Therapeutics (NASDAQ:SPRO) Receives Hold Rating from TD CowenTD Cowen restated a "hold" rating on shares of Spero Therapeutics in a research note on Monday.November 18, 2024 | marketbeat.comTD Cowen downgrades Spero Therapeutics (SPRO) to a HoldNovember 18, 2024 | markets.businessinsider.comSpero Therapeutics: Strategic Shift and Earnings UpdateNovember 16, 2024 | markets.businessinsider.comSpero Therapeutics, Inc.: Spero Therapeutics Announces Third Quarter 2024 Operating Results and Provides a Business UpdateNovember 15, 2024 | finanznachrichten.deSpero Therapeutics' (SPRO) Overweight Rating Reaffirmed at Cantor FitzgeraldCantor Fitzgerald reiterated an "overweight" rating on shares of Spero Therapeutics in a research note on Friday.November 15, 2024 | marketbeat.comSpero Therapeutics Announces Third Quarter 2024 Operating Results and Provides a Business UpdateNovember 14, 2024 | globenewswire.comSpero Therapeutics (SPRO) Set to Announce Earnings on ThursdaySpero Therapeutics (NASDAQ:SPRO) will be releasing earnings after the market closes on Thursday, November 14, Zacks reports.November 8, 2024 | marketbeat.comQ3 EPS Estimate for Spero Therapeutics Boosted by AnalystSpero Therapeutics, Inc. (NASDAQ:SPRO - Free Report) - Equities research analysts at HC Wainwright upped their Q3 2024 earnings per share (EPS) estimates for Spero Therapeutics in a research report issued to clients and investors on Monday, November 4th. HC Wainwright analyst R. Selvaraju now forNovember 6, 2024 | marketbeat.comHC Wainwright Lowers Spero Therapeutics (NASDAQ:SPRO) Price Target to $5.00HC Wainwright cut their price objective on Spero Therapeutics from $7.00 to $5.00 and set a "buy" rating for the company in a research note on Monday.November 4, 2024 | marketbeat.comSpero’s stock slides after antibiotic flops in Phase II trialNovember 1, 2024 | msn.comCambridge biotech pulls plug on lung disease drug, cuts 39% of workforceNovember 1, 2024 | bizjournals.comSpero suspends development of SPR720, to reduce workforce by 39%October 30, 2024 | markets.businessinsider.comSpero Therapeutics Restructures Focus on Key R&D ProjectsOctober 30, 2024 | markets.businessinsider.comSpero Therapeutics Stock Falls 21%, Cuts Jobs, Suspends Pulmonary Treatment Development ProgramOctober 29, 2024 | marketwatch.comSpero Therapeutics Announces SPR720 Phase 2a Interim Results and Provides a Business UpdateOctober 29, 2024 | markets.businessinsider.comSpero to cut 39% of workforce on failed study, stock plunges 20%October 29, 2024 | seekingalpha.comSpero Therapeutics, Inc. (NASDAQ:SPRO) Stock Has Shown Weakness Lately But Financials Look Strong: Should Prospective Shareholders Make The Leap?October 27, 2024 | finance.yahoo.com Remove Ads Get Spero Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for SPRO and its competitors with MarketBeat's FREE daily newsletter. Email Address SPRO Media Mentions By Week SPRO Media Sentiment Learn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. SPRO News Sentiment▼1.890.79▲Average Medical News Sentiment SPRO News Coverage Learn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. SPRO Articles This Week▼11▲SPRO Articles Average Week Remove Ads Get Spero Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for SPRO and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies Actuate Therapeutics News Molecular Partners News Rezolute News AC Immune News Protara Therapeutics News DiaMedica Therapeutics News Inhibikase Therapeutics News Puma Biotechnology News Tango Therapeutics News Journey Medical News Headlines Tools Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:SPRO) was last updated on 4/16/2025 by MarketBeat.com Staff From Our PartnersThe Crypto Market is About to Change LivesI've discovered something so significant about the 2025 crypto market that I had to put everything else aside ...Crypto 101 Media | Sponsored[Action Required] Claim Your FREE IRS Loophole GuideThis shouldn't surprise anyone who's been paying attention, but... Pres. Trump may be about to unleash the ...Colonial Metals | SponsoredWarning: “DOGE Collapse” imminentElon Strikes Back You may already sense that the tide is turning against Elon Musk and DOGE. Just this week...Altimetry | SponsoredCrypto’s crashing…but we’re still profitingMost traders are panicking right now. Bitcoin’s dropping. Altcoins are bleeding. The stock market’s a mess....Crypto Swap Profits | SponsoredNow I look stupid. Real stupid... I thought what happened 25 years ago was a once- in-a-lifetime event… but how wrong I was. Because here we...Porter & Company | SponsoredGold Hits New Highs as Global Markets SpiralWhen Trump took office in 2017, gold was just $1,100 an ounce. By the time he left, it had soared to $1,839. ...Premier Gold Co | SponsoredNew “Trump” currency proposed in DCAccording to one of the most connected men in Washington… A surprising new bill was just introduced in Wash...Paradigm Press | SponsoredIs it CRAZY to still want reliable profits, despite this market?Larry Benedict, the acclaimed "Market Wizard," is calling an emergency briefing now... The same Larry who –...Brownstone Research | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Spero Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Spero Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Buy SPRO Stock Free SPRO Stock Alerts